Datapoint: FDA Approves Aurinia’s Lupus Drug

The FDA last week approved Aurinia Pharma’s Lupkynis for the treatment of lupus nephritis, an inflammation of the kidneys in lupus patients that can lead to renal failure. This is the FDA’s second lupus nephritis approval in recent months. GlaxoSmithKline’s more broad lupus therapy Benlysta in December scored the first-in-class nod, and currently holds preferred status, with utilization management restrictions, for 15% of all covered lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 1/25/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 3

Datapoint: AstraZeneca, Merck Pull Lynparza in Ovarian Cancer

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 29

Datapoint: Nebraska Awards Medicaid Contracts

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 28

Datapoint: Lilly Scores Sweeping Label Expansion for Retevmo

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today